Tokai Pharmaceuticals Inc. (Nasdaq: TKAI) announced that it plans to discontinue the ARMOR3-SV clinical trial, the company’s pivotal Phase 3 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Hot Corp. News Trader Talk Trading Halts

BMO Capital Downgrades Tokai Pharmaceuticals (TKAI) to Market PerformJuly 26, 2016 10:44 AM BMO Capital Downgrades Tokai Pharmaceuticals (TKAI) to Market PerformJuly 26, 2016 10:43 AM Stifel Downgrades Tokai Pharmaceuticals (TKAI) to HoldJuly 26, 2016 9:45 AM Janney Montgomery Scott Downgrades Tokai Pharmaceuticals (TKAI) to NeutralJuly 26, 2016 8:50 AM Wells Fargo Downgrades Tokai Pharmaceuticals (TKAI) to Market PerformJuly 26, 2016 8:23 AM Tokai Pharmaceuticals Announces Clinical UpdateJuly 26, 2016 7:00 AM